Metformin added to standard treatment for newly diagnosed glioblastoma
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study tests whether adding metformin to the usual treatment for newly diagnosed glioblastoma (GBM) can improve outcomes. It involves taking metformin after surgery along with standard care (the Stupp protocol).
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult (age 18 or older) with newly diagnosed GBM (brain tumor grade 4) confirmed by pathology after surgery
- After surgery, the tumor must be IDH-wildtype and MGMT gene testing must show either low (hypomethylation) or high (hypermethylation) methylation
- Have a good enough day-to-day function after surgery (Karnofsky Performance Status above 60) and expected survival of at least 6 months
- Have kidney function strong enough for metformin (creatinine clearance 60 mL/min or higher) and no serious liver problems based on exam/tests
- Not have diabetes, not be taking metformin or other “biguanide” medicines, and not have allergies/intolerance to metformin
- For pregnancy risk: if applicable, have a negative pregnancy test and agree to effective birth control during treatment and for 4 weeks after the last dose; avoid pregnancy or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding metformin to standard radiation and temozolomide (chemo) can improve outcomes for people with newly diagnosed glioblastoma of a specific metabolic subtype. It aims to see if this combination is safer and more effective than standard treatment alone.
This study tests whether using a continuous glucose monitor (a small device that tracks blood sugar levels) can help manage high blood sugar in people newly diagnosed with glioblastoma, a type of brain cancer. It aims to see if this monitoring can improve overall health during treatment.
This Phase 1/2 study tests whether “glutamate inhibitor” medications can be safely added for newly diagnosed glioblastoma, and how they affect treatment outcomes. It’s designed for adults who will also receive the standard chemo‑radiation plan with temozolomide.
This study is testing whether special MRI scans and blood tests can help tell the difference between true tumor growth (progression) and a treatment-related reaction called 'pseudoprogression' in people with glioblastoma. The goal is to make treatment decisions more accurate.
This Phase 3 study tests whether metformin can improve brain function, behavior, and thinking in children and teens who were treated for certain brain tumors. You may be able to join if you meet age, time-since-treatment, language, and health/lab safety requirements.
This study tests a new medicine (MT-125) combined with standard radiation and chemotherapy for people with newly diagnosed glioblastoma that has a specific gene change (MGMT methylated). The goal is to see if it is safe and tolerable, and to look for early signs it might help.
Hear when a new Glioblastoma, IDH-wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.